<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730470</url>
  </required_header>
  <id_info>
    <org_study_id>U3P1287/01</org_study_id>
    <nct_id>NCT00730470</nct_id>
  </id_info>
  <brief_title>Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Open-label, Dose-Finding Study to Assess the Safety and Tolerability of U3-1287 (AMG 888), a Human Monoclonal Antibody Targeting HER3 in Patients With Advanced Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U3 Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U3 Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 clinical study to investigate the safety, pharmacokinetics, and
      pharmacodynamics of U3-1287 (AMG 888), a fully human monoclonal antibody targeting the HER3
      receptor, in patients with advanced solid tumors. Eligible patients will have disease that is
      refractory or resistant to standard treatments or for which no standard therapy exists. The
      study will be conducted in two parts; a dose escalation (Part 1) and a dose expansion (Part
      2). The hypothesis for this study is that U3-1287 (AMG888) will be safe and well tolerated in
      patients with advanced solid tumors and will show initial evidence of anti-tumor activity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of U3-1287 (AMG888) in patients with advanced solid tumors</measure>
    <time_frame>Lenth of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate maximum tolerated dose (MTD) of U3-1287(AMG888) when administered intravenously to patients with advanced solid tumors</measure>
    <time_frame>Lenth of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Parameters</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human anti-human antibody profile for U3-1287(AMG888)</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>U3-1287 (AMG888)</intervention_name>
    <description>IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Pathologically or cytologically documented advanced solid tumor that is refractory to
             standard treatment, for which no standard therapy is available, or the patient refuses
             standard therapy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

          -  Men or women at least 18 years of age

          -  Adequate hematologic, cardiac, renal, hepatic, metabolic, and coagulation function

        Key Exclusion Criteria:

          -  Presence of untreated or symptomatic brain metastasis.

          -  Presence of ascites or pleural effusion requiring chronic medical intervention.

          -  Uncontrolled hypertension

          -  Concurrent or previous (within 1 week of study day 1) anticoagulation therapy, except
             low-dose warfarin (≤ 2 mg/day) or low dose,low molecular weight heparin for
             prophylaxis against central venous catheter thrombosis.

          -  Recent major surgical procedure or not yet recovered from major surgery

          -  Recent participation in clinical drug trials.

          -  Participation in other investigational procedures.

          -  Unresolved toxicities from prior anti-cancer therapy

          -  Patient who is pregnant (e.g. positive human choriogonadotropin [HCG] test) or
             nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dana Faber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Centre</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram cancer Centre</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>July 28, 2010</last_update_submitted>
  <last_update_submitted_qc>July 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Alan Boyd MD</name_title>
    <organization>U3 Pharma GmbH</organization>
  </responsible_party>
  <keyword>Human Epidermal Growth Factor Receptor 3</keyword>
  <keyword>HER3</keyword>
  <keyword>Heregulin</keyword>
  <keyword>erb B3</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Phase I Clinical Study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

